Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia
Muhammad Imran Butt, Khalid Mania Alkhalifah, Muhammad Riazuddin, Saud Mohammed Almuammar, Salman Mohammed Almuammar, Ghayda Abdulkader Alhifthi, Fahad Wali Ahmed, Samia Mohamed Al Hashim, Najeeb Waheed · 2024
Read Efficacy and safety of semaglutide: real-world tertiary care experience from Saudi Arabia by Muhammad Imran Butt, Khalid Mania Alkhalifah, Muhammad Riazuddin, Saud Mohammed Almuammar, Salman Mohammed Almuammar, Ghayda Abdulkader Alhifthi, Fahad Wali Ahmed, Samia Mohamed Al Hashim, Najeeb Waheed (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11627033.txt.
Description
A peer-reviewed research article from Europe PMC (2024). BACKGROUND: Semaglutide, a glucagon-like peptide-1, is an effective antidiabetic drug promoting weight loss and providing cardiovascular protection. The original trials did not include participants from Saudi Arabia; hence, the study's findings are expected to be useful.OBJECTIVES: Explore the efficacy, safety, and favorable effects of once-weekly subcutaneous semaglutide (1 mg) in patients with type 2 diabetes and those who received it as an off-license prescription without having diabetes.DESIGN: Retrospective review of medical records.SETTING: Department of medicine at our institution.PATIENTS AND METHODS: This retrospective
Catalog record
| CREATOR | Muhammad Imran Butt, Khalid Mania Alkhalifah, Muhammad Riazuddin, Saud Mohammed Almuammar, Salman Mohammed Almuammar, Ghayda Abdulkader Alhifthi, Fahad Wali Ahmed, Samia Mohamed Al Hashim, Najeeb Waheed |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |